| Cat.# |
CB1026 |
| Size |
100
µg / 200 ml |
| Isotype:
|
Affinity
purified rabbit IgG
|
| Epitope: |
15
amino acid residues surrounding human VEGFR2 phospho-Tyr1054. |
| Species: |
human,
mouse |
| Storage: |
Store at 4°
for frequent use; at -20°
for at least one year |
| MW:
|
230
kDa
|
|
Application:
|
WB
|
| Dilution:
|
1:1000
|
|
Background:
VEGFR1
(Flt-1) and VEGFR2 (KDR/Flk-1) play an important role in regulating
physiological as well as pathological angiogenesis. VEGFR2 has strong
tyrosine kinase activity, and transduces the major signals for
angiogenesis. However, unlike other representative tyrosine kinase
receptors which use the Ras pathway, VEGFR2 mostly uses the
Phospholipase-Cg-Protein kinase-C pathway to activate MAP-kinase and DNA
synthesis. VEGFR2 is a direct signal transducer for pathological
angiogenesis including cancer and diabetic retinopathy, thus, VEGFR2
itself and the signaling appear to be critical targets for the
suppression of these diseases1,2. Upon binding to its ligand most commonly including VEGF-A and
VEGF-E, VEGFR2 undergoes dimerization and becomes activated.
Autophosphorylation of tyrosine 1054 in its kinase catalytic domain is
required for tyrosine kinase activity3.
References:
1.
Olsson, A. K. et al: Nat Rev Mol Cell Biol 7:359-71,
2006
2.
Shibuya,
M.: J Biochem Mol Biol. 39:469-78, 2006
3.
Paz,
K. & Zhu, Z.: Front Biosci. 10:1415-39, 2005
|
|
HUVEC
(CAI Cat# 200-05n) were starved overnight and then
stimulated with VEGF-A (100ng/ml for 2 min). The cell lysates were
subjected to Western blot analysis using phospho-VEGFR2 (Tyr1054)
specific antibody (A) and total VEGFR2 antibody (B).
|
